Literature DB >> 10553500

Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes.

G Prevost1, I Fajardy, P Fontaine, P M Danze, C Besmond.   

Abstract

Advanced glycation end products (AGEs) are believed to play an important role in the development of diabetic complications. AGEs increase in diabetes and modulate cellular functions through binding to a specific cell surface receptor (RAGE). The RAGE gene maps to chromosome 6p in the HLA class III area and is telomeric to the class II region at 250 kb from DRA. A recent report described the characterization of a major RAGE gene variant as a biallelic single base polymorphism (G/A 557) in the exon 3 sequence leading to a change of a glycine to a serine at position 82. Using DGGE and PCR-RFLP, we have investigated the distribution of this dimorphism in conjunction with HLA class II genes in large populations of type 1 diabetic patients and healthy subjects. Although no association of this RAGE gene polymorphism with disease susceptibility was found, we report a strong linkage disequilibrium between the variant carrying the serine amino acid at position 82 and two HLA-DR2 and HLA-DR4 specificities. In particular, we describe two major extensive HLA class II haplotypes associated with this serine variant and identified as DRB1*0401-DQA1*0301-DQB1*0301 in the diabetic group and DRB1*1501-DQA1*0102-DQB1*0602 in control individuals. These data were partially confirmed by family transmission analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553500     DOI: 10.1046/j.1365-2370.1999.00168.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN: 0960-7420


  7 in total

1.  Is there any association between GLY82 ser polymorphism of rage gene and Turkish diabetic and non diabetic patients with coronary artery disease?

Authors:  Ozlem Kucukhuseyin; Hulya Yilmaz-Aydogan; C Selim Isbir; Turgay Isbir
Journal:  Mol Biol Rep       Date:  2011-09-25       Impact factor: 2.316

2.  Association between the RAGE G82S polymorphism and Alzheimer's disease.

Authors:  Keshen Li; Dawei Dai; Bin Zhao; Lifen Yao; Songpo Yao; Binyou Wang; Ze Yang
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

Review 3.  Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochem Pharmacol       Date:  2010-01-22       Impact factor: 5.858

4.  Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma.

Authors:  Ling Zeng; An-qiang Zhang; Wei Gu; Jian Zhou; Lian-yang Zhang; Ding-yuan Du; Mao Zhang; Hai-yan Wang; Jun Yan; Ce Yang; Jian-xin Jiang
Journal:  Crit Care       Date:  2012-07-24       Impact factor: 9.097

5.  Soluble RAGE: a hot new biomarker for the hot joint?

Authors:  Bernhard Moser; Barry I Hudson; Ann Marie Schmidt
Journal:  Arthritis Res Ther       Date:  2005-06-03       Impact factor: 5.156

Review 6.  Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism.

Authors:  Marine Serveaux-Dancer; Matthieu Jabaudon; Isabelle Creveaux; Corinne Belville; Raïko Blondonnet; Christelle Gross; Jean-Michel Constantin; Loïc Blanchon; Vincent Sapin
Journal:  Dis Markers       Date:  2019-02-04       Impact factor: 3.434

7.  Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis.

Authors:  Lisa Carroll; Ian H Frazer; Malcolm Turner; Thomas H Marwick; Ranjeny Thomas
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.